For how we live.
3 articles published between November 9, 2025 and September 12, 2026.
A randomised trial found the Portfolio diet cut LDL cholesterol by about 13%, and a large cohort study links closer adherence to lower cardiovascular risk. Its authors' industry funding belongs in the record.
An individual-participant meta-analysis of 123,940 people in 19 double-blind trials tested 66 label-listed harms. Four survived correction — none of them the ones patients hear about most.
The first phase 1 results for CTX310 show gene editing can switch off a lipid gene in the liver. The trial was designed to look for harm, not benefit, and one participant died suddenly.